Akari Therapeutics PLC (AKTX)
1.47
-0.23
(-13.53%)
USD |
NASDAQ |
May 02, 16:00
1.47
0.00 (0.00%)
After-Hours: 20:00
Akari Therapeutics Enterprise Value: 9.625M for May 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 01, 2024 | 9.625M |
| April 30, 2024 | 8.358M |
| April 29, 2024 | 6.296M |
| April 26, 2024 | 5.545M |
| April 25, 2024 | 5.584M |
| April 24, 2024 | 5.584M |
| April 23, 2024 | 5.743M |
| April 22, 2024 | 5.505M |
| April 19, 2024 | 5.396M |
| April 18, 2024 | 5.743M |
| April 17, 2024 | 5.039M |
| April 16, 2024 | 5.311M |
| April 15, 2024 | 5.663M |
| April 12, 2024 | 5.743M |
| April 11, 2024 | 4.871M |
| April 10, 2024 | 6.456M |
| April 09, 2024 | 6.575M |
| April 08, 2024 | 7.248M |
| April 05, 2024 | 7.327M |
| April 04, 2024 | 7.565M |
| April 03, 2024 | 8.437M |
| April 02, 2024 | 8.120M |
| April 01, 2024 | 8.120M |
| March 28, 2024 | 8.496M |
| March 27, 2024 | 8.463M |
| Date | Value |
|---|---|
| March 26, 2024 | 8.628M |
| March 25, 2024 | 8.727M |
| March 22, 2024 | 8.132M |
| March 21, 2024 | 8.264M |
| March 20, 2024 | 8.726M |
| March 19, 2024 | 8.992M |
| March 18, 2024 | 9.389M |
| March 15, 2024 | 9.191M |
| March 14, 2024 | 9.654M |
| March 13, 2024 | 10.38M |
| March 12, 2024 | 10.32M |
| March 11, 2024 | 10.38M |
| March 08, 2024 | 10.32M |
| March 07, 2024 | 10.85M |
| March 06, 2024 | 10.71M |
| March 05, 2024 | 11.11M |
| March 04, 2024 | 11.04M |
| March 01, 2024 | 11.24M |
| February 29, 2024 | 11.71M |
| February 28, 2024 | 10.85M |
| February 27, 2024 | 11.31M |
| February 26, 2024 | 11.85M |
| February 23, 2024 | 11.64M |
| February 22, 2024 | 10.98M |
| February 21, 2024 | 11.51M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
3.016M
Minimum
Mar 30 2023
135.22M
Maximum
Feb 19 2021
42.04M
Average
39.72M
Median
Enterprise Value Benchmarks
| DBV Technologies SA | -12.56M |
| Adaptimmune Therapeutics PLC | 149.25M |
| Biodexa Pharmaceuticals Plc | -1.818M |
| NuCana PLC | -13.53M |
| Genfit SA | 156.58M |
Enterprise Value Related Metrics
| Earnings Yield | -139.1% |